MedWorm: Benign Prostatic Hyperplasia

Efficacy of quercetin in treatment of benign prostatic hyperplasia in a double-blind randomized clinical trial in Iran — 2011

Contraception — Thu, 09 Feb 2012 03:36:55 +0100

In this study, we assessed the efficacy of quercetin drop in alleviating BPH symptoms. (Source: Contraception)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Regulation of cell proliferation through a KIT‐mediated mechanism in benign prostatic hyperplasia

The Prostate — Tue, 07 Feb 2012 05:00:00 +0100

CONCLUSIONSThis is the first report to suggest that KIT regulates cell proliferation in the prostate and plays a significant role in the pathophysiology of BPH. Our study may lead to a greater understanding of the mechanism of BPH and provide a therapeutic target. Prostate © 2012 Wiley Periodicals, Inc. (Source: The Prostate)

A panel of five circulating microRNAs as potential biomarkers for prostate cancer

The Prostate — Wed, 01 Feb 2012 05:00:00 +0100

CONCLUSIONSOur data suggested that circulating miRNAs could serve as biomarkers for CaP, and compared to single miRNA, the 5 miRNAs panel can accurately discriminate CaP from BPH and healthy controls with high sensitivity and specificity, and therefore, combined with routine PSA test, these 5 CaP‐specific miRNAs may help improve CaP diagnosis in clinical application. Prostate © 2012 Wiley Periodicals, Inc. (Source: The Prostate)

Clinical and safety profiles of bipolar transurethral vaporization of the prostate in saline: A preliminary report

Asian Journal of Endoscopic Surgery — Fri, 27 Jan 2012 11:25:37 +0100

AbstractTransurethral vaporization of the prostate in saline (TURisV) is an innovative endoscopic surgical modality for the treatment of benign prostatic hyperplasia (BPH) that vaporizes prostate tissue using a uniquely designed mushroom electrode. TURisV promises instant hemostatic tissue ablation under saline irrigation and offers clinical advantages for endoscopic BPH operations. From July 2008 to February 2009, TURisV was performed in 17 cases with clinically significant BPH. Median operation time was 127.0 min and median volume of vaporized prostate tissue was 41.1 g. Median International Prostate Symptom Score improved from 20 to 4 after 12 months. Median maximum flow rate increased from 5.3 mL/s to 13.8 mL/s after 12 months. Postoperative median residual urine improved from ...

Dutasteride for Low-Risk Prostate Cancer: Debate Heats UpDutasteride for Low-Risk Prostate Cancer: Debate Heats Up

Medscape Today Headlines — Tue, 24 Jan 2012 13:47:52 +0100

The benign prostatic hyperplasia drug has the makings of a treatment for men on active surveillance, say the authors of a new study. No way, say critics. Medscape Medical News (Source: Medscape Today Headlines)

The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population

Annals of Oncology — Tue, 24 Jan 2012 05:00:00 +0100

Conclusions: These results suggest that hOGG1 is associated with the susceptibility to CaP and its aggressive clinicopathological characteristics. (Source: Annals of Oncology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Isoflavones in Treating Watchful Waiting Benign Prostate Hyperplasia: A Double-Blinded, Randomized Controlled Trial

The Journal of Alternative and Complementary Medicine — Mon, 23 Jan 2012 21:46:25 +0100

The Journal of Alternative and Complementary Medicine Jan 2012, Vol. 18, No. 1: 54-60. (Source: The Journal of Alternative and Complementary Medicine)

Referral Criteria for Benign Prostatic Hyperplasia in Primary Care. The 2011 Update.

Actas Urologicas Espanolas — Mon, 23 Jan 2012 05:00:00 +0100

Authors: Cózar JM, Castiñeiras J PMID: 22277292 [PubMed - as supplied by publisher] (Source: Actas Urologicas Espanolas)

Is There a Relationship Between Bladder Outlet Obstruction due to Benign Prostatic Hyperplasia and Pulmonary Thromboembolism?

Journal of Forensic Sciences — Mon, 23 Jan 2012 05:00:00 +0100

Authors: Rosenfeld HE, Byard RW Abstract Benign prostatic hyperplasia with chronic bladder outlet obstruction has been associated with deep venous thrombosis (DVT) and fatal pulmonary thromboembolism (PTE). To evaluate this further, 60 autopsy cases of men with PTE were compared with 60 age-matched controls. The criteria for outlet obstruction were macroscopic prostatic enlargement with bladder trabeculation and benign prostatic hyperplasia on microscopy. Ten of the 60 men (16.7%) with fatal PTE had evidence of bladder outlet obstruction (age 57-78 years; mean 71.4 years). Of the 60 controls, 12 had evidence of bladder outlet obstruction (20%) (age 67-86 years; mean 75.5 years). No significant relationship could be demonstrated between bladder outlet obstruction and fat...

The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor.

Urologic Oncology — Thu, 19 Jan 2012 05:00:00 +0100

CONCLUSIONS: Our study suggests reciprocal regulation of PlncRNA-1 and androgen receptor contribute to CaP pathogenesis and that PlncRNA-1 is a potential therapy target. PMID: 22264502 [PubMed - as supplied by publisher] (Source: Urologic Oncology)

GreenLight HPS™ 120‐W laser vaporization vs transurethral resection of the prostate (

BJU International — Wed, 18 Jan 2012 05:00:00 +0100

CONCLUSIONS• Bladder storage symptoms may represent a major concern, although they are of limited duration in patients undergoing PVP.• High‐power PVP can achieve and maintain the same results as TURP over a period of 24 months. (Source: BJU International)

MedWorm Sponsor Message: Find the best January Sales in the UK.

New clinical evidence of silodosin, an α1A selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms

International Journal of Urology — Tue, 17 Jan 2012 05:00:00 +0100

Abstract: Lower urinary tract symptoms associated with benign prostatic hyperplasia are highly prevalent in older men. Pharmacological treatment is the first‐line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. The first choice in the pharmacological treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia is the α1‐adrenoceptor antagonists. Many α1‐adrenoceptor antagonists are available in the world. Silodosin is an α1‐adrenoceptor antagonist developed by Kissei Pharmaceutical, and has a specific selectivity for the α1A‐adrenoceptor subtype. By antagonizing α1A‐adrenoceptor in the prostate and urethra, silodosin causes smooth muscle relaxation in the lower urinary tract. As a result of the high aff...

Outpatient Simultaneous Treatment of Benign Prostatic Hyperplasia and Bladder Lithiasis with GreenLight™ and Holmium Laser*

Journal of Endourology — Mon, 16 Jan 2012 15:28:26 +0100

Journal of Endourology , Vol. 0, No. 0. (Source: Journal of Endourology)

FDA approves drugs for BPH, AF

Modern Medicine — Sun, 15 Jan 2012 05:00:00 +0100

FDA has approved tadalafil to treat benign prostatic hyperplasia in patients with or without erectile dysfunction and rivaroxaban to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. (Source: Modern Medicine)

N-acetyltransferase-2 gene polymorphisms and prostate cancer susceptibility in Latin American patients

Medical Oncology — Fri, 13 Jan 2012 16:51:24 +0100

Abstract We investigated the role of N-acetyltransferases (NAT) in prostate cancer (PCa) susceptibility. NAT are polymorphic in the population and metabolize important carcinogenic products directly involved in the tumor initiation process. This prospective case–control study utilized the polymerase chain reaction-based restriction fragment length polymorphism method and comprised a cohort of consecutive 478 individuals: 126 men with prostate cancer; 101 men with benign prostatic hyperplasia (BPH); and a control health population of 177 female and 74 male blood donors from the same region. NAT2 slow or fast acetylators genotypes were determined by the combination of four variant alleles. Lifetime occupational history, dietary patterns, cigarette smoking and other anamnest...

Recent Advances in Surgery for Benign Prostatic HyperplasiaRecent Advances in Surgery for Benign Prostatic Hyperplasia

Medscape Today Headlines — Thu, 12 Jan 2012 04:00:00 +0100

Transurethral resection has been the standard treatment for benign prostatic hyperplasia, but are other options available? Therapeutic Advances in Urology (Source: Medscape Today Headlines)

Natural history of lower urinary tract symptoms in Japanese men from a 15‐year longitudinal community‐based study

BJU International — Wed, 11 Jan 2012 05:00:00 +0100

CONCLUSION• In a 15‐year‐longitudinal community‐based study for Japanese men, we have shown that the IPSS and quality of life index deteriorated, PV and PSA level increased, and Qmax decreased. (Source: BJU International)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Effects of Melandrium firmum methanolic extract on testosterone-induced benign prostatic hyperplasia in Wistar rats.

Asian Journal of Andrology — Mon, 09 Jan 2012 05:00:00 +0100

In this study, we investigated whether the Melandrium firmum methanolic extract (MFME) improves BPH, using the testosterone propionate (TP)-induced BPH rat model. Castration was performed via the scrotal route under sodium pentobarbital anaesthesia. BPH in castrated rats was generated via daily subcutaneous injections of TP (3 mg kg(-1)) dissolved in corn oil, for 4 weeks. MFME was administered daily by oral gavage at a dose of 200 mg kg(-1) for 4 weeks, along with the TP injections. The control group received injections of corn oil subcutaneously. At the scheduled termination of the experiment, all rats were killed and their prostates weighed; the relative prostate weight (prostate/body weight ratio) was calculated, and histomorphological changes in the prostate were examined. Additiona...

Botulinum toxin type A for the treatment of lower urinary tract disorders

International Journal of Urology — Fri, 06 Jan 2012 05:00:00 +0100

AbstractMany papers report the clinical success of botulinum toxin A as a method of management of various bladder dysfunctions. The rationale was that botulinum toxin A was able to block the presynaptic release of acetylcholine from the parasympathetic efferent nerve. The efficacy might result not only from an inhibitory effect on detrusor muscle, but also some effects might be mediated by altering the afferent nerve input. This systematic literature review discusses the efficacy and safety of botulinum toxin A therapy for idiopathic detrusor overactivity, neurogenic detrusor overactivity, interstitial cystitis/painful bladder syndrome and benign prostatic hyperplasia. The information was gathered from a PubMed literature research for abstracts from recent urological meetings. Inject...

Bipolar Vaporization of the ProstateBipolar Vaporization of the Prostate

Medscape Today Headlines — Thu, 05 Jan 2012 11:19:05 +0100

Is bipolar vaporization a safe and effective alternative to transurethral resection in the treatment of benign prostatic hyperplasia? Therapeutic Advances in Urology (Source: Medscape Today Headlines)

Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection

BMC Urology - Latest articles — Wed, 04 Jan 2012 05:00:00 +0100

Conclusions: These results support the hypothesis that OnabotA activates apoptotic pathways in the rat prostate through a mechanism that involves sympathetic outflow impairment. (Source: BMC Urology - Latest articles)

Testosterone prevents prostate inflammation in metabolic syndrome

Society for Endocrinology — Tue, 03 Jan 2012 12:00:00 +0100

High-fat diet (HFD)-induced metabolic syndrome is associated with hypogonadism and prostate inflammation. Vignozzi and colleagues sought to uncover the effects of testosterone supplementation on these effects. Male rabbits fed a HFD were treated with testosterone which resulted in the increased expression of mRNA of prostate proinflammatory markers and ameliorated all HFD-induced features, including hypoxia and fibrosis. These results may be informative in the prevention of benign prostate hyperplasia and lower urinary tract symptoms. Vignozzie et al. (2012) Journal of Endocrinology 212 71–84. Read the full article at: DOI:10.1530/JOE-11-0289. (Source: Society for Endocrinology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling

AJP: Endocrinology and Metabolism — Tue, 03 Jan 2012 05:00:00 +0100

In conclusion, our data show that T positively regulates PDE5 expression and functional activities in prostate, and T ablation not only suppresses prostate size but also reduces prostatic SM contractility, with several potential SM contraction/relaxation pathways implicated. Zaprinast findings strongly suggest a major role for PDE5/cGMP in this signaling cascade. PDE5 inhibition may represent a novel mechanism for treatment of BPH. (Source: AJP: Endocrinology and Metabolism)

Correlates for nocturia: A review of epidemiological studies

International Journal of Urology — Sun, 01 Jan 2012 05:00:00 +0100

AbstractTraditionally, nocturia was considered to be one of the symptoms of prostatism. However, this symptom has unusual characteristics compared with other lower urinary tract symptoms; for example, there is only a mild benefit for nocturia from treatment for benign prostatic hyperplasia. In the past decade, nocturia has been investigated as a separate symptom in epidemiological studies. These types of studies have shown various correlates for nocturia other than benign prostatic hyperplasia, as well as the prevalence of this symptom. These correlates include age, race/ethnicity, medical problems (such as hypertension, diabetes and stroke) psychological aspects, tasting habits, quality of life and even mortality. The cause‐and‐effect associations are not always obvious between noctur...

Getting Up at Night Frequently to Urinate May Represent Nocturia

About Sleep Disorders — Fri, 30 Dec 2011 05:00:00 +0100

In a condition that is more common as we get older, especially in men, getting up to pee during the night may plague your sleep. It is characterized by frequent awakenings due to a need urinate, but what is nocturia? What are some of the common causes? In our youth, our bodies are able to concentrate our urine and allow us to sleep uninterrupted. However, this mechanism begins to become less effective as we get older for various reasons. For example, our kidneys may not be able to concentrate our urine as much as they could previously. In addition, older men often have benign prostatic hyperplasia (BPH), which can lead to an inability to fully empty the bladder and more frequent trips to the bathroom, even at night. Aging may not be the only issue, however. In fact, simply drinking too m...

Prostatic Urethral Lift: Two-year Results After Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Urology — Thu, 29 Dec 2011 05:43:46 +0100

Conclusion: The present study demonstrated that LUTS and flow improvements without compromising sexual function. Although this was an early study with a small cohort, this therapy shows promise as a new option for patients with LUTS. (Source: Urology)

Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures.

Asian Journal of Andrology — Mon, 26 Dec 2011 05:00:00 +0100

Authors: Larré S, Camparo P, Comperat E, Boulbés D, Haddoum M, Baulande S, Soularue P, Costa P, Cussenot O Abstract Pygeum africanum (Tadenan) is a popular phytotherapeutic agent used in the treatment of symptomatic benign prostatic hyperplasia. The active compounds of the drug have not been identified, and determining the plasma concentration of the drug is, therefore, not possible. Because there are conflicting results on the efficacy of this drug, we aimed to investigate its effect on prostate cell growth in vitro using human serum collected before and after Pygeum africanum intake. We used primary and organotypic cultures of human prostatic stromal myofibroblast cell line WPMY and prostatic epithelial cell line PNT2. We also used fresh benign prostatic tissue. The serum of a ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms

Andrologia — Fri, 23 Dec 2011 05:00:00 +0100

SummaryLower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are frequently encountered in ageing males. We compared the efficacy of alfuzosin 10 mg alone or in combination with sildenafil 50 mg in the treatment of LUTS due to benign prostatic hyperplasia. One hundred male patients older than 45 years were randomized to two groups containing 50 patients each; one group receiving alfuzosin 10 mg and the other group alfuzosin 10 mg combined with sildenafil 50 mg. International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), prostate volume and post‐void residual urine were evaluated. The mean age was 60.2 ± 17.8. Mean data of evaluated parameters in both groups at the end of 3rd month compared with baseline values are given respective or...

Nymox Announces New $15 Million Equity Financing Commitment

Medical News (via PRIMEZONE) — Thu, 22 Dec 2011 13:30:00 +0100

HASBROUCK HEIGHTS, N.J., Dec. 22, 2011 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that the Company has secured commitment for $15 million in equity financing from institutional investors. The new funding will be used for general corporate purposes including the Company's current Phase 3 U.S. trials for NX-1207, Nymox's late stage drug in development for benign prostatic hyperplasia (BPH). The financing gives the Company the right to place common stock to the investors at a 3% discount to the market price of the Company's stock. There are no warrants, price resets, and no restrictions on other corporate financing. The timing and amount of each placement is in the sole discretion of the Company. (Source: Medical News (via PRIMEZONE))

Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population.

Genetics and Molecular Research — Thu, 22 Dec 2011 03:54:02 +0100

Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population. Genet Mol Res. 2011;10(4):3038-45 Authors: Qadri Q, Sameer AS, Shah ZA, Hamid A, Alam S, Manzoor S, Siddiqi MA Abstract Glutathione-S-transferase P1 (GSTP1) is a critical enzyme of the phase II detoxification pathway. One of the common functional polymorphisms of GSTP1 is A→G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1. To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia case...

Serum Levels of Secreted Group IIA Phospholipase A2 in Benign Prostatic Hyperplasia and Prostate Cancer: A Biomarker for Inflammation or Neoplasia?

Inflammation — Wed, 21 Dec 2011 20:07:47 +0100

In conclusion, these findings suggest that cancer-related changes are not exclusive factors contributing to elevated serum sPLA2-IIA levels and emphasize the utility of sPLA2-IIA as a circulating marker of inflammation in patients with BPH and PCa. Content Type Journal ArticlePages 1-6DOI 10.1007/s10753-011-9418-1Authors Mario Menschikowski, Institute of Clinical Chemistry and Laboratory Medicine, Medical Faculty “Carl Gustav Carus”, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, GermanyAlbert Hagelgans, Institute of Clinical Chemistry and Laboratory Medicine, Medical Faculty “Carl Gustav Carus”, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, GermanySusanne Fuessel, Department of Urology, Medical Faculty “Carl Gustav Carus”, Tec...

Prognostic value of promoter hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in prostate cancer

Chinese Journal of Cancer Research — Wed, 21 Dec 2011 19:52:13 +0100

Conclusion Hypermethylation of RARB and p16 promoters may predict prognosis in prostate cancer. Content Type Journal ArticleCategory Original ArticlePages 306-311DOI 10.1007/s11670-011-0306-xAuthors A. Ameri, Department of Radiation Oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranA. Alidoosti, Department of Radiation Oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranY. Hosseini, Department of Urology, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranM. Parvin, Department of Pathology, Shahid Labbafinezhad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranM. H. Emranpour, Department of Radiation Oncology, Imam Hossein Hospital...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Re: Clinical Outcomes After Combined Therapy With Dutasteride Plus Tamsulosin or Either Monotherapy in Men With Benign Prostatic Hyperplasia (BPH) by Baseline Characteristics: 4-Year Results From the Randomized, Double-Blind Combination of Avodart and Tamsulosin (CombAT) Trial

The Journal of Urology — Mon, 19 Dec 2011 05:00:00 +0100

C. G. Roehrborn, J. Barkin, P. Siami, A. Tubaro, T. H. Wilson, B. B. Morrill and R. P. Gagnier Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas (Source: The Journal of Urology)

Re: Comparison of Dutasteride and Finasteride for Treating Benign Prostatic Hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)

The Journal of Urology — Mon, 19 Dec 2011 05:00:00 +0100

J. C. Nickel, P. Gilling, T. L. Tammela, B. Morrill, T. H. Wilson and R. S. Rittmaster Department of Urology, Queen's University, Kingston, Ontario, Canada (Source: The Journal of Urology)

Re: Progression of Null or Mild Lower Urinary Tract Symptoms Indicative of Benign Prostatic Hyperplasia After 2 Years of Follow-Up in Non-Treated Men Aged 40 Years or Older

The Journal of Urology — Mon, 19 Dec 2011 05:00:00 +0100

J. Moreno Sierra, C. Fernandez Pérez, S. Cano Escudero, M. Fuentes Ferrer, L. Barreales Tolosa and A. Silmi Moyano Department of Urology, Research Unit, Hospital Clínico, San Carlos, Madrid, Spain (Source: The Journal of Urology)

Association of overactive bladder and C‐reactive protein levels. Results from the Boston Area Community Health (BACH) Survey

BJU International — Fri, 16 Dec 2011 05:00:00 +0100

CONCLUSIONS• Results show a consistent association of increasing CRP levels and OAB among both men and women.• These results support our hypothesis for the role of inflammation in the development of OAB and a possible role for anti‐inflammatory agents in its treatment. (Source: BJU International)

Comparative Study Between Laparoscopic Extraperitoneal and Open Adenomectomy.

Actas Urologicas Espanolas — Fri, 16 Dec 2011 05:00:00 +0100

CONCLUSIONS: LEA is a relatively complex technique that requires laparoscopic skills, but it is a feasible and safe alternative to open surgery and has several advantages. PMID: 22178347 [PubMed - as supplied by publisher] (Source: Actas Urologicas Espanolas)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Quartz Head Contact Laser Fiber: A Novel Fiber for Laser Ablation of the Prostate Using the 980 nm High Power Diode Laser

The Journal of Urology — Fri, 16 Dec 2011 05:00:00 +0100

Conclusions: The quartz head contact fiber can produce similarly good outcomes in ablating the prostate using the high power 980 nm diode laser compared to the side firing fiber, and with fewer complications and side effects. (Source: The Journal of Urology)

Finasteride Adherence-Associated Factors in Chinese Benign Prostatic Hyperplasia Patients

Urologia Internationalis : Last 20 articles — Wed, 14 Dec 2011 23:00:00 +0100

Urol Int (DOI:10.1159/000334416) (Source: Urologia Internationalis : Last 20 articles)

Differential Expression of the Androgen-Conjugating UGT2B15 and UGT2B17 Enzymes in Prostate Tumor Cells during Cancer Progression.

The Journal of Clinical Endocrinology and Metabolism — Wed, 14 Dec 2011 05:00:00 +0100

Conclusions:The current study reveals that UGT2B15 and UGT2B17 are differentially regulated during prostate cancer progression. Furthermore, this study also identifies the UGT2B15 gene as a negatively regulated target gene in castration-resistant prostate cancer and lymph node metastases. PMID: 22170718 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer

International Braz J Urol — Wed, 14 Dec 2011 02:22:41 +0100

CONCLUSIONS: Changes in inflammation and endothelial activation markers may be not considered to be of value in discriminating BPH and PCa. (Source: International Braz J Urol)

Estrogen receptor {beta} and 17{beta}-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer [Medical Sciences]

Proceedings of the National Academy of Sciences — Tue, 13 Dec 2011 05:00:00 +0100

Estrogen receptor β (ERβ) is activated in the prostate by 5α-androstane-3β,17β-diol (3β-Adiol) where it exerts antiproliferative activity. The proliferative action of the androgen receptor is activated by 5α-dihydrotestosterone (DHT). Thus, prostate growth is governed by the balance between androgen receptor and ERβ activation. 3β-Adiol is a high-affinity ligand and agonist of ERβ and is derived from DHT by 3-keto reductase/3β-hydroxysteroid dehydrogenase enzymes. Here, we demonstrate that, when it is expressed in living cells containing an estrogen response element-luciferase reporter, 17β-hydroxysteroid dehydrogenase type 6 (17βHSD6) converts the androgen DHT to the estrogen 3β-Adiol, and this leads to activation of the ERβ reporter. This conversion of DHT occurs at concen...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Re: "Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial"

American Journal of Epidemiology — Mon, 12 Dec 2011 05:00:00 +0100

(Source: American Journal of Epidemiology)

Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue.

Asian Journal of Andrology — Mon, 12 Dec 2011 05:00:00 +0100

This study was designed to investigate the association between immune inflammation and androgen receptor (AR) expression in benign prostatic hyperplasia (BPH). We retrospectively analyzed 105 prostatectomy specimens. An immune inflammation score for each specimen was defined by combining three immunohistochemical markers (CD4, CD8 and CD20). The immunohistochemical markers were CD4 and CD8 for T lymphocytes, CD20 for B lymphocytes and AR antibody for the AR in BPH samples. Rates of CD4, CD8, CD20 and AR expression in BPH were 20 (19.0%), 21 (20.0%), 101 (96.2%) and 48 (45.7%), respectively. Total prostate volume (TPV) was higher in the immune inflammation group than in the non-immune inflammation group (62.7 ml vs. 49.2 ml, t=2.482, P<0.05). Patients in the immune inflammation group h...

Vegetational variation of phenolic compounds in Epilobium angustifolium.

Natural Product Research — Fri, 09 Dec 2011 05:00:00 +0100

Authors: Jürgenson S, Matto V, Raal A Abstract Epilobium angustifolium L. herbs are used in ethnomedicine to treat benign prostate hyperplasia. The aim of the study was to investigate the phenolic contents in distinct E. angustifolium organs during the whole vegetational period from May to October. The plants were obtained from a remote habitat in Estonia and spectrophotometrically analysed for the total polyphenol, tannin, and flavonoid contents. The total polyphenol content was the highest in roots (85 mg g(-1)) and stems (67 mg g(-1)) in July. The total flavonoid content was the highest in leaves (2.36 mg g(-1)) and flowers (2.09 mg g(-1)) and it remained relatively stable during the summer months. The highest tannin content was found in small growing plants in ...

Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension

Clinical Drug Investigation — Sun, 04 Dec 2011 07:01:28 +0100

(Source: Clinical Drug Investigation)

Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men.

The Urologic Clinics of North America — Sun, 04 Dec 2011 03:21:50 +0100

Authors: Mazur DJ, Helfand BT, McVary KT Abstract As men age, there is an increase in the frequency of pathologic diseases affecting the genitourinary tract. Most notable among these changes are the rising prevalence of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). The pathogenesis of these conditions seems to be multifactorial and includes age-related changes in the nervous system and neuroregulatory factors, such as nitric oxide and RhoA/Rho-kinase. Various pharmacologic agents that target these pathways, such as α-blockers and PDE-5is, underscore the contribution of neuroregulatory factors on the development of LUTS/BPH and ED. PMID: 22118347 [PubMed - in process] (Source: The Urologic Clinics of North Ame...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Effect of doxazosin on expression of eNOS in rat kidney in the presence of partial bladder outlet obstruction.

Journal of Nephrology — Fri, 02 Dec 2011 05:00:00 +0100

Conclusion: These findings may provide insight into the beneficial and restorative effects of a1-adrenoceptor antagonists on eNOS expression in the kidney, when used to treat symptoms of benign prostate hyperplasia and hypertension. PMID: 22135033 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)

New Benefits of Blockbuster Drug Cialis Discovered; Sales Expected To...

PRWeb: Medical Pharmaceuticals — Thu, 01 Dec 2011 19:16:33 +0100

Recent Research Supervised by the FDA Indicates Treatment with the Erectile Dysfunction Drug Tadalafil (Cialis) is Also Effective in the Treatment of Benign Prostatic Hyperplasia (BPH)....(PRWeb November 30, 2011)Read the full story at http://www.prweb.com/releases/2011/11/prweb8802338.htm (Source: PRWeb: Medical Pharmaceuticals)

Reply

Urology — Thu, 01 Dec 2011 05:00:00 +0100

We would like to thank Scarpa et al for elegant comment on our report: “Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment.” In accordance with previous reports, our results suggest that serum C-reactive protein (CRP) levels have a significant association with storage symptoms, but not with voiding symptoms, in 408 men with lower urinary tract symptoms. The serum CRP levels decreased significantly after medical treatment for lower urinary tract symptoms (unpublished data). From these findings, we speculated that chronic inflammation has a greater association with storage symptoms than with voiding symptoms. Chronic inflammation of bladder might play a role in the occurrence of urgency, inde...

Editorial Comment

Urology — Thu, 01 Dec 2011 05:00:00 +0100

The authors retrospectively reviewed the cases of 305 patients who had undergone transurethral electro-resection of the prostate (TURP) for benign prostatic hyperplasia (BPH). The purpose of their analysis was to determine whether there was an increase in perioperative cardiovascular events in patients who had their routine anticoagulation stopped before the procedure. (Source: Urology)

Preservation of Sexual Function with the Prostatic Urethral Lift: A Novel Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

The Journal of Sexual Medicine — Thu, 01 Dec 2011 05:00:00 +0100

Conclusions. We demonstrated significant improvement in LUTS with no evidence of degradation in erectile or ejaculatory function after treatment with the prostatic urethral lift procedure. This procedure warrants further study as a new option for patients underserved by current treatments for LUTS/BPH. Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P, Thavaseelan J, and McVary KT. Preservation of sexual function with the prostatic urethral lift: A novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

The role of secreted frizzled‐related protein 2 expression in prostate cancer

Histopathology — Thu, 01 Dec 2011 05:00:00 +0100

Conclusions: These results imply: (i) that there is a loss of SFRP‐2 expression from benign to malignant prostate glands; and (ii) differential SFRP‐2 expression among two possible subgroups of Gleason grade 5 tumours. (Source: Histopathology)

A multicentre single-blind randomized controlled trial comparing bipolar and monopolar transurethral resection of the prostate.

Canadian Urological Association Journal — Thu, 01 Dec 2011 05:00:00 +0100

CONCLUSION: This trial suggests equivalent short-term outcomes for men undergoing monopolar or bipolar TURP. PMID: 22154630 [PubMed - in process] (Source: Canadian Urological Association Journal)

Correlations Among Cardiovascular Risk Factors, Prostate Blood Flow, and Prostate Volume in Patients With Clinical Benign Prostatic Hyperplasia

Urology — Thu, 01 Dec 2011 05:00:00 +0100

Conclusion: Prostate vascular resistance in patients with BPH has positive correlations with cardiovascular risk factors and prostate size. These findings suggest that prostate hypoxia might play a role in the pathogenesis of BPH. (Source: Urology)

Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.

International Journal of Clinical Chemistry — Tue, 29 Nov 2011 05:00:00 +0100

CONCLUSION: Our preliminary results showed that we were able to identify specific autoantibody signatures that can differentiate prostate cancer from BPH, and may result in the reduction of unnecessary biopsies in patients with increased serum PSA. PMID: 22146597 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Chemistry)

Long-Term Followup after Electrocautery Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia

Infectious Diseases in Obstetrics and Gynecology — Mon, 28 Nov 2011 16:09:15 +0100

Conclusion. This study shows modern TURP still produces durable improvement in voiding symptoms which remains comparable with historic studies. This study, however, found a marked drop in early complications but, conversely, a higher than expected incidence of urethral strictures. (Source: Infectious Diseases in Obstetrics and Gynecology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Re: The Efficacy of Additive Tolterodine Extended Release for 1-Year in Older Men With Storage Symptoms and Clinical Benign Prostatic Hyperplasia

The Journal of Urology — Mon, 28 Nov 2011 05:00:00 +0100

S. D. Chung, H. C. Chang, B. Chiu, C. H. Liao and H. C. Kuo Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Ban Ciao and Graduate Institution of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (Source: The Journal of Urology)

Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia

BJU International — Fri, 25 Nov 2011 05:00:00 +0100

CONCLUSIONS• TWOC has become a standard practice worldwide for men with BPH and AUR.• In most cases, an α1‐blocker is prescribed before TWOC and significantly increases the chance of success.• Prolonged catheterization is associated with an increased morbidity. (Source: BJU International)

Re: Association of Clinical Benign Prostate Hyperplasia With Prostate Cancer Incidence and Mortality Revisited: A Nationwide Cohort Study of 3,009,258 Men

The Journal of Urology — Fri, 25 Nov 2011 05:00:00 +0100

D. D. Ørsted, S. E. Bojesen, S. F. Nielsen and B. G. Nordestgaard Department of Clinical Biochemistry, Herlev Hospital and Faculty of Health Sciences, Copenhagen University Hospital, Copenhagen, Denmark (Source: The Journal of Urology)

Re: Transurethral Ethanol Ablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Long-Term Follow-Up

The Journal of Urology — Fri, 25 Nov 2011 05:00:00 +0100

T. El-Husseiny and N. Buchholz Barts and London NHS Trust, London, United Kingdom (Source: The Journal of Urology)

Re: Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia

The Journal of Urology — Fri, 25 Nov 2011 05:00:00 +0100

J. M. Pisco, L. C. Pinheiro, T. Bilhim, M. Duarte, J. R. Mendes and A. G. Oliveira Department of Radiology, Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal (Source: The Journal of Urology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Re: A Placebo-Controlled Study Investigating the Efficacy and Safety of the Phosphodiesterase Type 5 Inhibitor UK-369,003 for the Treatment of Men With Lower Urinary Tract Symptoms Associated With Clinical Benign Prostatic Hyperplasia

The Journal of Urology — Fri, 25 Nov 2011 05:00:00 +0100

N. A. Tamimi, I. Mincik, S. Haughie, J. Lamb, A. Crossland and P. Ellis Pfizer Ltd., Sandwich, Kent, United Kingdom (Source: The Journal of Urology)

Re: Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia: K. T. McVary, C. G. Roehrborn, A. L. Avins, M. J. Barry, R. C. Bruskewitz, R. F. Donnell, H. E. Foster, Jr., C. M. Gonzalez, S. A. Kaplan, D. F. Penson, J. C. Ulchaker and J. T. Wei J Urol 2011; 185: 1793–1803

The Journal of Urology — Fri, 25 Nov 2011 05:00:00 +0100

This article and the full guideline document are exemplars of the guideline process. However, there are a number of clarifications that would have been helpful. (Source: The Journal of Urology)

Transurethral resection of prostate with plasmakinetic energy: 100 months results of a prospective randomized trial

BJU International — Thu, 24 Nov 2011 05:00:00 +0100

CONCLUSION• Our 100 months results suggest that Plasmakinetic technology can be used as a first‐line treatment instead of monopolar TURP. (Source: BJU International)

Relaxant and contractile responses of detrusor muscle strips obtained from bladder outlet-obstructed rats treated with doxazosin enantiomers.

Canadian Journal of Physiology and Pharmacology — Thu, 24 Nov 2011 05:00:00 +0100

In conclusion, although (-)doxazosin inhibits vascular functional α(1)-adrenoceptors more weakly than (+)doxazosin, both agents equally ameliorate the enhanced responses in detrusor muscle of BOO rats, suggesting that the chiral carbon atom in the molecular structure of doxazosin does not affect its beneficial effects in the bladder smooth muscle of BOO rats. PMID: 22115277 [PubMed - as supplied by publisher] (Source: Canadian Journal of Physiology and Pharmacology)

Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.

Wiener Klinische Wochenschrift — Wed, 23 Nov 2011 05:00:00 +0100

CONCLUSION: Different frequencies in distinctly lymphocyte subpopulation in peripheral blood of healthy men, BPH and PC patients could be responsible for occurrence and progression of prostatic hyperplasia or tumour. Due to the ability of tumours to suppress the cognate T cell immune response, the cells of innate immunity (NKT and Tregs) may be playing a key role in the immunopathogenesis of PC and BPH. PMID: 22105113 [PubMed - as supplied by publisher] (Source: Wiener Klinische Wochenschrift)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Abdominal Rebounding Pain Without Sepsis in a 66-year-old Man

Gastroenterology — Wed, 23 Nov 2011 05:00:00 +0100

Question: A 66-year-old man was referred to our hospital because of progressive abdominal pain. He had experienced subumbilical dull pain accompanied by anorexia and dyspepsia for 2 days before he consulted the hospital. Change in bowel habits or weight loss was not noted. He had a history of benign prostate hyperplasia that was controlled by tamsulosin (α-blocker), left renal cell carcinoma (RCC; stage T2N0M0) treated with radical nephrectomy (6 years ago), and sarcomatoid carcinoma of the lung over the right lower zone (, arrow) that was managed by oral chemotherapy with uracil-tegafur in the oncology division for 3 years. (Source: Gastroenterology)

Diabetes Treatment and Progression of Benign Prostatic Hyperplasia in Community-dwelling Black and White Men

Urology — Wed, 23 Nov 2011 05:00:00 +0100

Conclusion: These findings suggest that the presence of diabetes and subsequent poor glycemic control might be less related to prostate growth and more to the dynamic components of lower urinary tract function. Additional evaluations of the associations between glycemic control and BPH progression are warranted. (Source: Urology)

Bravery in an Interior Battle: An Impending Encounter with Polyps

Psychology Today Anxiety Center — Tue, 22 Nov 2011 21:51:45 +0100

He has no proof—no documentary evidence. But he does have a suspicion. Yes, for sure, the Pilgrims left England to escape constraints on their faith; they sailed to the new world where they would enjoy religious freedom. Primary Topic: Health read more (Source: Psychology Today Anxiety Center)

Primary carcinoid tumor of the urinary bladder with prominent subnuclear eosinophilic granules.

Pathology, Research and Practice — Tue, 22 Nov 2011 05:00:00 +0100

We report here a case of primary carcinoid tumor of the urinary bladder with an unusual cytological feature in a 72-year-old Japanese man. A bladder polypoid mass was incidentally found by ultrasonography during the follow-up of a benign prostate hyperplasia. Histological examination of the transurethrally resected tissue revealed that the upper part of the mass was a tumor showing tubuloglandular anastomosing structures. Most of the tumor cells had peculiar subnuclear eosinophilic granules. The features of the granules were reminiscent of those observed in neuroendocrine cells of the intestine. The tumor cells were immunohistochemically positive for chromogranin A and synaptophysin. The tumor was diagnosed as carcinoid tumor of pure form of the urinary bladder. The lower part of the mass ...

Acoustic Radiation Force Impulse Imaging of Human Prostates: Initial In Vivo Demonstration

Ultrasound in Medicine and Biology — Mon, 21 Nov 2011 05:00:00 +0100

Abstract: Reliably detecting prostate cancer (PCa) has been a challenge for current imaging modalities. Acoustic radiation force impulse (ARFI) imaging is an elasticity imaging method that uses remotely generated, focused acoustic beams to probe tissue stiffness. A previous study on excised human prostates demonstrated ARFI images portray various prostatic structures and has the potential to guide prostate needle biopsy with improved sampling accuracy. The goal of this study is to demonstrate the feasibility of ARFI imaging to portray internal structures and PCa in the human prostate in vivo. Custom ARFI imaging sequences were designed and implemented using a modified Siemens Antares™ scanner with a three-dimensional (3-D) wobbler, end-firing, trans-cavity transducer, EV9F4. Nineteen pa...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

A Fishy Nodule

Gastroenterology — Mon, 21 Nov 2011 05:00:00 +0100

Question: A 65-year-old patient presented with a painful epigastric mass. It had been diagnosed as a hematoma after a blunt abdominal trauma 3 months prior. Since then, the mass remained and continued to cause the patient pain. Past medical history included chronic alcohol consumption and benign prostatic hyperplasia. Upon physical examination, he was determined to have a hard, irregular mass in the epigastric area associated with an ulcerated, 1.5 cm large nodule of the umbilicus (). Laboratory tests revealed a mild anemia (10 g/dL) with a low prothrombin time (63%) and a total bilirubinemia of 26 mg/L. His serum alpha-fetoprotein concentration was 16.8 ng/mL. Thoracoabdominopelvic computed tomographic (CT) was performed. It revealed a 12 × 7-cm solid mass in the epigastric region associ...

Lycopene for the prevention of prostate cancer.

Cochrane Database of Systematic Reviews — Sun, 20 Nov 2011 22:06:03 +0100

CONCLUSIONS: Given that only three RCTs were included in this systematic review, and the high risk of bias in two of the three studies, there is insufficient evidence to either support, or refute, the use of lycopene for the prevention of prostate cancer. Similarly, there is no robust evidence from RCTs to identify the impact of lycopene consumption upon the incidence of prostate cancer, prostate symptoms, PSA levels or adverse events. PMID: 22071840 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

Red ginseng and 20(S)-Rg3 control testosterone-induced prostate hyperplasia by deregulating androgen receptor signaling

Journal of Natural Medicines — Sat, 19 Nov 2011 16:52:18 +0100

Abstract Since prostate growth is governed by the androgen signaling pathway, blockade of the pathway is regarded as an appropriate strategy for the treatment of benign prostatic hyperplasia (BPH). Panax ginseng is known to have various pharmacological activities. Of several products of its root, red ginseng, having many bioactive ginsenosides, is most popularly used in Korea, and recently has been reported to control the proliferation of cancer cells. We here tested the effect of a water extract of Korean red ginseng (WKRG) on testosterone-induced prostate hyperplasia. WKRG (daily intraperitoneal injection) prevented prostate overgrowth and epithelial thickening induced by testosterone in rats, and suppressed a rat prostate kallikrein-S3. In human prostate cells, WKRG inh...

Lycopene for the prevention of prostate cancer

NeLM - Complementary Medicine — Fri, 18 Nov 2011 05:00:00 +0100

Source: Cochrane Library Area: Evidence > Complementary Medicine Background Prostate cancer is a common cause of death in developed countries, yet the benefits of screening for prostate cancer still remain controversial. A prostate-specific antigen (PSA) test result greater than 4 ng/mL (nanograms/millilitre) has commonly been used as the cut-off level for seeking further tests to diagnose the presence (or absence) of prostate cancer. An increase in PSA levels may not necessarily be associated with an increased risk of prostate cancer, as PSA levels may also be increased in men with benign prostatic hyperplasia and prostatitis. Despite the uncertainty of the net benefit of early detection and treatment, safe and effective methods to prevent prostate cancer are of value. Consumers, ...

Benign Prostate Specific Antigen Distribution and Associations With Urological Outcomes in Community Dwelling Black and White Men

The Journal of Urology — Wed, 16 Nov 2011 05:00:00 +0100

Conclusions: Results suggest that increased benign prostate specific antigen may help identify men with prostate cancer and those at risk for benign prostatic hyperplasia treatment. (Source: The Journal of Urology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

The Role of Bipolar Transurethral Vaporization in the Management of Benign Prostatic Hyperplasia

Urologia Internationalis : Last 20 articles — Thu, 10 Nov 2011 23:00:00 +0100

Urol Int (DOI:10.1159/000329797) (Source: Urologia Internationalis : Last 20 articles)

Low serum testosterone levels are predictive of prostate cancer

World Journal of Urology — Wed, 09 Nov 2011 07:03:21 +0100

Conclusions This study supports experimental findings that testosterone levels are predictor of prostate cancer and that prostate cancer is frequently associated with low testosterone levels. In the diagnostic work-up for prostate cancer, adding testosterone determination to PSA test may improve predictive accuracy. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00345-011-0793-xAuthors Luigi Mearini, Urology Department, University of Perugia, Sant’Andrea delle Fratte, 06100 Perugia, ItalyAlessandro Zucchi, Urology Department, University of Perugia, Sant’Andrea delle Fratte, 06100 Perugia, ItalyElisabetta Nunzi, Urology Department, University of Perugia, Sant’Andrea delle Fratte, 06100 Perugia, ItalyTommaso Villirillo, Urology Depart...

Outline of JUA clinical guidelines for benign prostatic hyperplasia

International Journal of Urology — Tue, 01 Nov 2011 04:00:00 +0100

This article is a shortened version of the English translation. The Guidelines were formulated on the basis of evidence retrieved from the PubMed database between 1995 and 2009, as well as other relevant sources. The target patients of these Guidelines are men with suspected BPH, and the target users are urologists. A mandatory assessment should include a medical history, a physical examination, the completion of symptom and quality of life questionnaires, urinalysis, prostate ultrasonography, measurement of serum prostate specific antigen and postvoid residual urine, and an uroflowmetry. Optional tests include a bladder diary, the measurement of serum creatinine, and upper urinary tract ultrasonography. Care should be taken to not overlook coexisting diseases such as an infection or malig...

JUA clinical guidelines for benign prostatic hyperplasia

International Journal of Urology — Tue, 01 Nov 2011 04:00:00 +0100

This article is an English translation of the abridged version of the Guidelines. The Guidelines were formulated on the basis of evidence retrieved from the PubMed database between 1995 and 2009, as well as other relevant sources. The target patients of these Guidelines are men with suspected BPH, and the target users are urologists. A mandatory assessment should include a medical history, a physical examination, the completion of symptom and quality of life questionnaires, a urinalysis, a prostate ultrasonography, measurement of serum prostate specific antigen and postvoid residual urine, and uroflowmetry. Optional tests include keeping a bladder diary, the measurement of serum creatinine, and upper urinary tract ultrasonography. Care should be taken to not overlook coexisting diseases su...

Bipolar Plasmakinetic Transurethral Resection of Prostate in 132 Consecutive Patients With Large Gland: Three-year Follow-up Results

Urology — Mon, 31 Oct 2011 04:00:00 +0100

Conclusion: PK-TURP represents an effective surgical intervention for the treatment of bladder outlet obstruction for large prostates. Furthermore, the functional results at 3 years demonstrated durability. Therefore, the PK-TURP technique could play an important role in the surgical treatment of patients with symptomatic benign prostatic hyperplasia with a large prostate gland. (Source: Urology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Focus on Phosphodiesterase Inhibitors for the Treatment of Erectile Dysfunction in Older Men.

Clinical Therapeutics — Sat, 29 Oct 2011 04:00:00 +0100

CONCLUSION: PDEIs are effective for erectile dysfunction and well tolerated in older men. PMID: 22036514 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)

Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: A prospective open‐label long‐term study using frequency–volume chart

Neurourology and Urodynamics — Fri, 28 Oct 2011 04:00:00 +0100

ConclusionsThe present long‐term prospective study using FVC demonstrated that tamsulosin reduced nighttime urine production in BPH patients with NP. Neurourol. Urodynam. © 2011 Wiley Periodicals, Inc. (Source: Neurourology and Urodynamics)

Bladder mechanoreceptor changes after artificial bladder outlet obstruction in the anesthetized rat

Neurourology and Urodynamics — Fri, 28 Oct 2011 04:00:00 +0100

ConclusionsRats with BOO had bladder mechanoreceptors with higher threshold volumes and lower tension sensitivity. Such changes would result in a weaker afferent drive of the micturition reflex. Similar changes may contribute to the development of residual urine and retention in patients with BOO. Neurourol. Urodynam. © 2011 Wiley Periodicals, Inc. (Source: Neurourology and Urodynamics)

Treatment of refractory trigeminal neuralgia with intravenous phenytoin.

American Journal of Health-System Pharmacy : AJHP — Wed, 26 Oct 2011 10:00:56 +0100

Conclusion Phenytoin sodium 15 mg/kg i.v. divided into two doses separated by four hours was safe and effective in treating an acute exacerbation of refractory TN. PMID: 22011984 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)

Re: The Diagnostic Value of Abdominal Ultrasound, Urine Cytology and Prostate-Specific Antigen Testing in the Lower Urinary Tract Symptoms Clinic

The Journal of Urology — Wed, 26 Oct 2011 04:00:00 +0100

N. S. Patel, C. Blick, P. V. Kumar and P. R. Malone Department of Urology, Churchill Hospital, Oxford, United Kingdom (Source: The Journal of Urology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Re: Mortality Trends for Benign Prostatic Hyperplasia and Prostate Cancer in English Populations 1979–2006

The Journal of Urology — Wed, 26 Oct 2011 04:00:00 +0100

M. E. Duncan and M. J. Goldacre Unit of Health-Care Epidemiology, Department of Public Health, University of Oxford, Oxford, United Kingdom (Source: The Journal of Urology)

Impact of Plasmakinetic Enucleation of the Prostate (PKEP) on Sexual Function: Results of a Prospective Trial

The Journal of Sexual Medicine — Mon, 24 Oct 2011 04:00:00 +0100

Conclusions. PKEP has no negative influence on the quality of erections measured by the self‐administered IIEF questionnaire, but it significantly lowers the orgasmic function domain score, reflecting probably postoperative retrograde ejaculation. These findings are important in preoperative counseling of the patients undergoing PKEP for symptomatic BPH. Zhao Z, Ma W, Xuan X, Ou L, Liang Y, and Zeng G. Impact of plasmakinetic enucleation of the prostate (PKEP) on sexual function: Results of a prospective trial. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Oxidative stress—cause or consequence of male genital tract disorders?

The Prostate — Mon, 24 Oct 2011 04:00:00 +0100

CONCLUSIONSThis study revealed that several male genital tract disorders—BPH and different forms of prostatitis (NIH categories IIIa, IIIb, and IV)—are tightly interconnected via OxS‐mediated pathways. Acknowledging OxS as an important pathogenesis mechanism of these diseases helps to open up new horizons for their treatment. Prostate © 2011 Wiley Periodicals, Inc. (Source: The Prostate)

Re: Pioglitazone Attenuates Prostatic Enlargement in Diet-Induced Insulin-Resistant Rats by Altering Lipid Distribution and Hyperinsulinaemia

The Journal of Urology — Mon, 24 Oct 2011 04:00:00 +0100

A. Vikram, G. Jena and P. Ramarao Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S. A. S. Nagar, Mohali, Punjab, India (Source: The Journal of Urology)

[Benign prostatic hyperplasia referral criteria for primary care, 2011 version.]

Atencion Primaria — Thu, 20 Oct 2011 04:00:00 +0100

Authors: Molero García JM, Pérez Morales D, Brenes Bermúdez F, Naval Pulido E, Fernández-Pro Pedraza A, Martín Jiménez JA, Castiñeiras Fernández J, Cozar Olmo JM PMID: 22019068 [PubMed - as supplied by publisher] (Source: Atencion Primaria)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Obesity, Physical Activity and Lower Urinary Tract Symptoms: Results From the Southern Community Cohort Study

The Journal of Urology — Thu, 20 Oct 2011 04:00:00 +0100

Conclusions: Severe obesity is associated with an increased risk of lower urinary tract symptoms at followup, while physical inactivity may permit progression of lower urinary tract symptoms in normal weight men regardless of race. These variables should be considered in future research into modifiable risk factors for lower urinary tract symptoms. (Source: The Journal of Urology)

The Mechanisms Underlying α1-Adrenoceptor Antagonists and Modulation of Bladder Function: An Emerging Role for Changes in Perfusion

The Journal of Urology — Wed, 19 Oct 2011 04:00:00 +0100

The objective evaluation of lower urinary tract function in patients with BPH via pressure flow studies shows that α1-AR antagonists decrease detrusor pressure on voiding and relieve benign prostatic obstruction. In addition, α1-AR antagonists have been reported to improve bladder storage function by increasing bladder volume and suppressing involuntary detrusor contractions. Although α1-AR antagonists ameliorate voiding symptoms by decreasing the smooth muscle tone of the prostate and the bladder neck, resulting in the relief of functional prostatic obstruction, the mechanisms underlying the improvement in storage symptoms and detrusor overactivity are unknown. (Source: The Journal of Urology)

Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study

International Journal of Clinical Practice — Sun, 16 Oct 2011 04:39:22 +0100

Conclusion: In this study, doxazosin‐GITS showed significantly more rapid onset of efficacy and similar AEs compared with tamsulosin in BPH patients with LUTS. We believe this will probably improve patient compliance. Future studies with a larger number of patients and a longer follow‐up period will be required to confirm this. (Source: International Journal of Clinical Practice)

Cialis to Treat Benign Prostatic Hyperplasia Approved by FDA

Disabled World — Thu, 13 Oct 2011 22:41:03 +0100

The U.S. Food and Drug Administration approves Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. Cialis was approved in 2003 for the treatment of ED. (Source: Disabled World)

The Impact of Current BPH Treatment on Sexual FunctionThe Impact of Current BPH Treatment on Sexual Function

Medscape Today Headlines — Thu, 13 Oct 2011 12:02:19 +0100

The recommended pharmacological treatments for benign prostatic hyperplasia-- 5-alpha reductase inhibitors and alpha-blockers--may all contribute to sexual dysfunction--as may the disease itself. International Journal of Clinical Practice (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Oral exposure to low-dose bisphenol A aggravates testosterone-induced benign hyperplasia prostate in rats

Toxicology and Industrial Health current issue — Thu, 13 Oct 2011 04:00:00 +0100

The declining level of androgen during aging, associated with an inclining level of estrogen, has been hypothesized to be important in the development of benign prostatic hyperplasia (BPH). Within physiologic range, increasing estrogen levels can stimulate prostate to develop and permanently increase prostate size. As an estrogenic endocrine disruptor, bisphenol A (BPA) might be stimulatory to prostate development. We further hypothesized that low dose BPA could induce hyperplasia prostate to proliferate and aggravate the symptom of BPH in male SD rats. BPH was induced by testosterone and then treated with BPA (10, 30, or 90 µg/kg, i.g., daily), 17β-estradiol (E2; 50.0 µg/kg, s.c., daily), or vehicle for 4 weeks. We found that weight and volume in rats treated with low dos...

Influences of Neuroregulatory Factors on the Development of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction in Aging Men

Urologic Clinics of North America — Thu, 13 Oct 2011 04:00:00 +0100

As men age, there is an increase in the frequency of pathologic diseases affecting the genitourinary tract. Most notable among these changes are the rising prevalence of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). The pathogenesis of these conditions seems to be multifactorial and includes age-related changes in the nervous system and neuroregulatory factors, such as nitric oxide and RhoA/Rho-kinase. Various pharmacologic agents that target these pathways, such as α-blockers and PDE-5is, underscore the contribution of neuroregulatory factors on the development of LUTS/BPH and ED. (Source: Urologic Clinics of North America)

Re: National, Regional, and Global Trends in Body-Mass Index Since 1980: Systematic Analysis of Health Examination Surveys and Epidemiological Studies With 960 Country-Years and 9.1 Million Participants

The Journal of Urology — Thu, 13 Oct 2011 02:40:05 +0100

M. M. Finucane, G. A. Stevens, M. J. Cowan, G. Danaei, J. K. Lin, C. J. Paciorek, G. M. Singh, H. R. Gutierrez, Y. Lu, A. N. Bahalim, F. Farzadfar, L. M. Riley and M. Ezzati; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index) (Source: The Journal of Urology)

Re: Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A 1-Year, Open-Label Extension Study

The Journal of Urology — Thu, 13 Oct 2011 02:40:05 +0100

C. F. Donatucci, G. B. Brock, E. R. Goldfischer, P. J. Pommerville, A. Elion-Mboussa, J. D. Kissel and L. Viktrup Department of Surgery, Division of Urology, Duke University, Durham, North Carolina (Source: The Journal of Urology)

Bioforce AG Research Department Identifies Significant Flaws In The...

PRWeb: Medical Pharmaceuticals — Wed, 12 Oct 2011 18:36:15 +0100

After evaluating this study the researchers are still convinced that standardized saw palmetto berry products are a good and safe treatment for mild to moderate Benign Prostatic Hyperplasia (BPH)(PRWeb October 10, 2011)Read the full story at http://www.prweb.com/releases/2011/10/prweb8861284.htm (Source: PRWeb: Medical Pharmaceuticals)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Saw palmetto extract does not reduce UT symptoms, study finds

Drug Topics - Clinical News — Wed, 12 Oct 2011 04:00:00 +0100

Researchers found saw palmetto extract did not reduce urinary tract symptoms in 369 men with benign prostatic hyperplasia, a study reported recently in JAMA. (Source: Drug Topics - Clinical News)

Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer

BJU International — Wed, 12 Oct 2011 04:00:00 +0100

What's known on the subject? and What does the study add?The male steroid hormone metabolism is an important target in the treatment of prostatic diseases. However, present literature is inconsistent about intraprostatic concentrations of steroid hormones and the role of intraprostatic steroid hormones in the arise and the course of prostatic diseases is yet to be determined.Part II of this two‐piece mini‐review reviews the effect of medication that alters the male steroid hormone metabolism (i.e. 5‐alpha reductase inhibitors, androgen deprivation therapy) on intraprostatic steroid hormone concentrations. Better knowledge of the intraprostatic steroid hormone concentrations might lead to more individualized treatment and even to new medical targets.Androgen deprivation therapy (ADT) ...

Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer

BJU International — Wed, 12 Oct 2011 04:00:00 +0100

What's known on the subject? and What does the study add?The male steroid hormone metabolism is an important target in the treatment of prostatic diseases. However, present literature is inconsistent about intraprostatic concentrations of steroid hormones and the role of intraprostatic steroid hormones in the arise and the course of prostatic disease is yet to be determined.Part I of this two‐piece reviews the different methods of steroid hormone measurement and gives an overview of steroid hormone concentrations in normal and diseased prostatic tissue. More accurate methods of measurement and increased knowledge of androgenic steroid hormonal pathways of the prostate could lead to better treatment of prostatic diseases.Owing to inconsistencies and methodological differences, the present...

Botulinum Toxin for Treatment of LUTS Secondary to BPHBotulinum Toxin for Treatment of LUTS Secondary to BPH

Medscape Today Headlines — Tue, 11 Oct 2011 15:55:00 +0100

Investigators conducted a randomized phase 2 clinical trial to explore the effects of onabotulinum toxin A on lower urinary tract symptoms secondary to benign prostatic hyperplasia. Medscape Urology (Source: Medscape Today Headlines)

Nymox NX-1207 BPH Drug to be Presented at Orlando Meeting of American Urological Association

Medical News (via PRIMEZONE) — Tue, 11 Oct 2011 14:00:00 +0100

HASBROUCK HEIGHTS, N.J., Oct. 11, 2011 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) will be presented on November 4, 2011 at the Mid-Atlantic/New England Section of the American Urological Association Meeting in Orlando, FL. The presentation is authored by Neal Shore MD FACS, of Myrtle Beach, SC, Sheldon Freedman MD FACS, of Las Vegas, NV, Barton Wachs, MD FACS, of Long Beach, CA and Barrett Cowan, MD FACS, of Denver, CO. (Source: Medical News (via PRIMEZONE))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Detrusor-Directed Therapy in Men With Benign Prostatic Hyperplasia

Current Bladder Dysfunction Reports — Tue, 11 Oct 2011 05:52:28 +0100

Abstract As men age, the incidence of benign prostatic hyperplasia and bothersome lower urinary tract symptoms increases. Until recently, treatment modalities focused on prostatic-directed management, but there has been a shift in focus as emerging research has implicated the bladder as a significant player in the development of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Although initially avoided in this population, recent studies have demonstrated the safety and efficacy of antimuscarinics. Epidemiologic studies illustrating the link between erectile dysfunction and lower urinary tract symptoms then led to the investigation of phosphodiesterase-5 inhibitors for symptom management. Novel agents, including β3 adrenoreceptor agonists, are now be...

Saw palmetto extract does not reduce UT symptoms, study finds

Drug Topics - Top News — Tue, 11 Oct 2011 04:00:00 +0100

Researchers found saw palmetto extract did not reduce urinary tract symptoms in 369 men with benign prostatic hyperplasia, a study reported recently in JAMA. (Source: Drug Topics - Top News)

Contribution of common medications to lower urinary tract symptoms in men

NeLM - News — Tue, 11 Oct 2011 04:00:00 +0100

Source: Arch Internal Med Area: News Although benign prostatic hyperplasia (BPH) is the most common cause, the aetiology of lower urinary tract symptoms (LUTS) is multifactorial. Clinical guidelines for BPH suggest evaluating other potential sources of LUTS (e.g. concomitant medication use) before initiating pharmacotherapy or surgical intervention. A study in the Archives of Internal Medicine has assessed the cross-sectional association between current use of selected common medications and LUTS among men enrolled in the California Men's Health Study (CMHS). It involved men aged 45 to 69 years from the Kaiser Permanente California Medical Care Program. A total of 84,170 participants completed questionnaires and were eligible for study inclusion. Following exclusions for a rang...

Saw palmetto extract does not reduce UT symptoms, study finds

Modern Medicine — Tue, 11 Oct 2011 04:00:00 +0100

Researchers found saw palmetto extract did not reduce urinary tract symptoms in 369 men with benign prostatic hyperplasia, a study reported recently in JAMA. (Source: Modern Medicine)

3-million-man study links BPH to prostate cancer

Modern Medicine — Mon, 10 Oct 2011 04:00:00 +0100

NEW YORK (Reuters Health) - Men with benign prostatic hyperplasia (BPH) are at higher risk both for prostate cancer and for dying from it, according to an analysis of three million Danish men followed for up to 27 years. (Source: Modern Medicine)

Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia: Profile Report

Drugs — Sun, 09 Oct 2011 09:28:59 +0100

(Source: Drugs)

FDA approves tadalafil to treat benign prostatic hyperplasia

Drug Topics - Top News — Sun, 09 Oct 2011 04:00:00 +0100

FDA has approved tadalafil (Cialis, Eli Lilly) for 3 indications: ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions. (Source: Drug Topics - Top News)

Modulation of YY1 and p53 expression by transforming growth factor-β3 in prostate cell lines.

Cytokine — Sat, 08 Oct 2011 21:45:56 +0100

Authors: Caggia S, Libra M, Malaponte G, Cardile V Abstract Transforming growth factor-β (TGF-β) is the prototype of a family of secreted polypeptide growth factors. These cytokines play very important roles during development, as well as in normal physiological and disease processes, by regulating a wide array of cellular processes, such as cell growth, differentiation, migration, apoptosis, and extracellular matrix production. TGF-β utilizes a multitude of intracellular signalling pathways in addition to Smads with actions that are dependent on circumstances, including dose, target cell type, and context. The aims of this research were (i) to verify the effects of dose-dependent TGF-β3 treatment on YY1 and p53 expression, in BPH-1 cell line, human benign prostate hyperplasia,...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Cialis Gets FDA Green Light For Enlarged Prostate Treatment

Health News from Medical News Today — Sat, 08 Oct 2011 17:00:00 +0100

The FDA announced that it has approved Eli Lily's answer to Viagra, known as Cialis, for the treatment of enlarged prostate. This should prove to be a boon for Eli Lily's blockbuster impotence medication. The FDA stated that Cialis can now be labelled for treatment of a non cancerous enlarged prostate, (called benign prostatic hyperplasia (BPH) and be used for people who have both BPH and erectile dysfunction. Nearly half of men over fifty suffer from enlarged prostate problems that can cause difficulty urinating... (Source: Health News from Medical News Today)

FDA Approves Cialis To Treat Benign Prostatic Hyperplasia

Health News from Medical News Today — Sat, 08 Oct 2011 08:00:00 +0100

The U.S. Food and Drug Administration today approved Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. Cialis was approved in 2003 for the treatment of ED. Common symptoms of BPH include difficulty in starting urination and a weak urine stream; a sudden urge to urinate; and more frequent urination including at night... (Source: Health News from Medical News Today)

Cialis® For Once Daily Use Now FDA-Approved To Treat Men With Signs And Symptoms Of Benign Prostatic Hyperplasia (BPH) And Men With Both ED And BP

Health News from Medical News Today — Sat, 08 Oct 2011 08:00:00 +0100

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil) tablets for once daily use for the treatment of men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH). The FDA also approved Cialis for once daily use for a separate indication for the treatment of the signs and symptoms of BPH. This means Cialis is now approved for three indications: ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions... (Source: Health News from Medical News Today)

Cialis(R) for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) and Men With Both Erectile Dysfunction (ED) and Signs and Symptoms of BPH

HSMN NewsFeed — Fri, 07 Oct 2011 12:46:09 +0100

Cialis for once daily use is the first and only medication approved to treat men with both ED and BPH INDIANAPOLIS, Oct. 7, 2011 (HSMN NewsFeed) -- Eli Lilly and Company (NYSE:LLY ) announced today that the U.S. Food and Drug Administration (FDA) has ... BiopharmaceuticalsEli Lilly, Cialis, tadalafil, erectile dysfunction, benign prostatic hyperplasia (Source: HSMN NewsFeed)

Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo‐Controlled, Double‐Blind Study

The Journal of Sexual Medicine — Fri, 07 Oct 2011 04:00:00 +0100

Conclusions. Tadalafil 5 mg significantly improved both ED and BPH‐related outcomes through 12 weeks and was well tolerated. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, and Secrest RJ. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: Results of a randomized, placebo‐controlled, double‐blind study. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Urological Disorders in Men: Urinary Incontinence and Benign Prostatic Hyperplasia

Journal of Pharmacy Practice — Fri, 07 Oct 2011 04:00:00 +0100

Urinary incontinence (UI) and benign prostatic hyperplasia (BPH) are 2 common urogenital problems in men. UI is associated with involuntary leakage of urine and lower urinary tract symptoms (LUTS) of urgency, frequency, and nocturia. Types of UI include functional, urge, stress, and overflow. Treatment for UI is based on the type of incontinence, patient-specific factors, and treatment preferences of both patients and health care providers. Options for the management of UI include environmental modifications, disposable incontinence products, pelvic floor exercises, pharmacotherapy, surgically implanted devices, and intermittent catheterization. BPH may be also associated with LUTS. Patient symptoms, assessed with a measurement tool such as the American Urological Association Symptom Index...

FDA approves tadalafil to treat benign prostatic hyperplasia

Drug Topics - Clinical News — Fri, 07 Oct 2011 04:00:00 +0100

Tadalafil (Cialis) approved in US to treat benign prostatic hyperplasia

NeLM - News — Fri, 07 Oct 2011 04:00:00 +0100

Source: FDA Area: News The FDA has approved tadalafil (Cialis) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. (Source: NeLM - News)

FDA approves tadalafil to treat benign prostatic hyperplasia

Modern Medicine — Fri, 07 Oct 2011 04:00:00 +0100

Cialis Approved for Benign Prostatic Hyperplasia

Physician's First Watch current issue — Fri, 07 Oct 2011 04:00:00 +0100

(Source: Physician's First Watch current issue)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Cialis (Tadalafil) Approved For Benign Prostatic Hyperplasia Treatment, USA

Health News from Medical News Today — Fri, 07 Oct 2011 03:00:00 +0100

Tadalafil (Cialis) has been approved by the FDA (Food and Drug Administration) for the treatment of BPH (benign prostatic hyperplasia) signs and symptoms - a condition in which the prostate gland enlarges. It has also been approved for the treatment of simultaneous BPH and ED (erectile dysfunction). Since 2003, the medication has been on the market legally in the USA for ED treatment... (Source: Health News from Medical News Today)

FDA Approves Cialis to Treat Benign Prostatic Hyperplasia

Drugs.com - New Drug Approvals — Fri, 07 Oct 2011 00:10:13 +0100

October 6, 2011 -- The U.S. Food and Drug Administration today approved Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH... (Source: Drugs.com - New Drug Approvals)

FDA Okays ED Drug for Enlarged Prostate

MedPage Today State Required CME — Thu, 06 Oct 2011 23:43:10 +0100

(MedPage Today) -- Tadalafil (Cialis), currently marketed for erectile dysfunction, also may be used to treat benign prostatic hyperplasia, the FDA said. (Source: MedPage Today State Required CME)

Tadalafil Approved for Benign Prostatic HyperplasiaTadalafil Approved for Benign Prostatic Hyperplasia

Medscape Today Headlines — Thu, 06 Oct 2011 23:11:22 +0100

The FDA also has approved the drug for treating both BPH and erectile dysfunction when the conditions occur together. Medscape Medical News (Source: Medscape Today Headlines)

FDA approves Cialis to treat benign prostatic hyperplasia

Food and Drug Administration — Thu, 06 Oct 2011 20:12:00 +0100

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study

International Braz J Urol — Tue, 04 Oct 2011 00:39:26 +0100

CONCLUSION: Tamsulosin OCAS® treatment led to significant improvements in LUTS, HUS and QoL in Thai patients with bladder outlet obstruction from BPH with few side effects. (Source: International Braz J Urol)

Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3 009 258 men

International Braz J Urol — Tue, 04 Oct 2011 00:39:26 +0100

CONCLUSIONS: Obesity and smoking showed increased CIPP (maximal Intravesical Peak Pressures generated by Cough). While reduced BMI is related to lower CIPP, smoking cessation does not appear to diminish CIPP. These findings suggest that weight loss may reduce incontinence by CIPP modulation. However, the benefits of smoking cessation without additional lifestyle modification, may have no benefit to improve urinary incontinence. (Source: International Braz J Urol)

Fatty acid composition of fruits of two forms of Serenoa repens

Chemistry of Natural Compounds — Mon, 03 Oct 2011 05:38:12 +0100

This study presents an analysis of the fatty acid content of saw palmetto fruits from both the yellow-green and the less-distributed waxy blue-green forms growing in the Rockdale Pineland Preserve in Miami-Dade County, Florida. Extracts of the fruits were analyzed by GC and GC/MS both before and after treatment with diazomethane. All the samples had a similar composition dominated by oleic acid (40%) and lauric acid (22%), with minor amounts of C6-C18 free fatty acids and their naturally occurring methyl and ethyl esters. Fatty acid methyl and ethyl esters were quantified for the first time. Neither qualitatively nor quantitatively significant differences could be found in the fatty acid composition of the fruits from yellow-green and blue-green plants. Content Type Journal Arti...

Serum C-reactive Protein Levels are Associated With Residual Urgency Symptoms in Patients With Benign Prostatic Hyperplasia After Medical Treatment

Urology — Mon, 03 Oct 2011 04:00:00 +0100

Objective: Urinary urgency is a common and bothersome symptom in patients with benign prostatic hyperplasia (BPH); this symptom may persist even after medical treatment. Chronic inflammation has been reported to be associated with the pathogenesis of BPH and lower urinary tract symptoms (LUTS). We investigate the association between serum C-reactive protein (CRP) level and residual urgency symptoms in BPH patients after medical treatment.Methods: Two-hundred-five men undergoing stable medical treatment for BPH, defined as a total prostate volume ≥40 mL, were enrolled. Patients with acute infection or those taking nonsteroid antiinflammatory drugs or aspirin were excluded. Uroflowmetry, postvoid residual volume, transrectal ultrasound parameters, serum prostate specific antigen (PSA), and...

Add‐on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α‐blocker treatment for lower urinary tract symptoms

BJU International — Sat, 01 Oct 2011 04:00:00 +0100

CONCLUSIONS• Flexible‐dose fesoterodine was well tolerated as an add‐on treatment in men with persistent storage symptoms.• Changes in urgency episodes at week 12 (primary endpoint) and many secondary endpoints were not significantly different between fesoterodine and placebo add‐on treatment; however, improvements in frequency and symptom bother were significantly greater with fesoterodine.• These data suggest that there remains a limited understanding of the optimal evaluation and treatment of men with LUTS. (Source: BJU International)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Immunohistochemical staining of slit2 in primary and metastatic prostatic adenocarcinoma.

Translational Oncology — Sat, 01 Oct 2011 04:00:00 +0100

CONCLUSIONS: To our knowledge, this represents the first study comparing the immunohistochemical profiles of Slit2 in PCa and Mets to specimens of HGPIN, BPH, NDP, and NAC. These findings suggest that Slit2 expression can be increased in HGPIN, PCa, and Mets, making it a potentially important biomarker for prostate cancer. PMID: 21966548 [PubMed - in process] (Source: Translational Oncology)

Editorial Comment

Urology — Sat, 01 Oct 2011 04:00:00 +0100

It is said that “Most new treatments work miracles for a while.” This is why we need clinical trials; but this is also why some of the new techniques have never made it into the list of “classical” treatments for lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH). (Source: Urology)

Reply

Urology — Sat, 01 Oct 2011 04:00:00 +0100

Actually gaining scientific acknowledgment as a viable alternative in benign prostatic hyperplasia (BPH) treatment is a real challenge for the newly emerging surgical techniques, because most of them do not manage to pass the test of time. (Source: Urology)

Systematic review of therapy for men with overactive bladder.

Canadian Urological Association Journal — Sat, 01 Oct 2011 04:00:00 +0100

Authors: Chapple C Abstract Lower urinary tract symptoms (LUTS) can have multiple causes in men. Overactive bladder (OAB) is an empirical diagnosis used as the basis for initial management after assessing symptoms, physical findings, urinalysis and other indicated evaluations. In men, the diagnosis is complicated by the potential of benign prostatic hyperplasia (BPH), which is a histological diagnosis. Although storage symptoms (i.e., those associated with OAB) are the most bothersome group of LUTS in men with BPH, these patients are usually treated with BPH rather than OAB drugs. The standard pharmacologic treatment of patients with bothersome voiding and storage LUTS at low risk of progression should be an α1-AR antagonist. The combination α1-AR antagonist + antimuscarinic agen...

S19 tamsulosin combined with dutasteride showed better efficacy versus its use in monotherapy in men with benign prostatic hyperplasia: a two-year follow up of 283 patients

European Urology Supplements — Sat, 01 Oct 2011 04:00:00 +0100

(Source: European Urology Supplements)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BPH - management in general practice.

Australian Family Physician — Sat, 01 Oct 2011 04:00:00 +0100

Authors: Charles J, Valenti L, Britt H Abstract From April 2009 to March 2011 in BEACH, benign prostatic hyperplasia/hypertrophy (BPH) was managed at a rate of six per 1000 general practice encounters with male patients aged 18 years and over, suggesting it was managed by general practitioners about 228 000 times per year nationally. PMID: 22003475 [PubMed - in process] (Source: Australian Family Physician)

A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml.

Indian J Med Res — Sat, 01 Oct 2011 04:00:00 +0100

This study was aimed at exploring the use of serum glyoxalase as a supplemental biomarker to differentiate between malignant vs non-malignant diseases of the prostate in patients with PSA in the range of 4-20 ng/ml. Methods: Serum glyoxalase and PSA were measured in 92 men (30 control, 31 cases of benign prostate hyperplasia (BPH) and 31 cases of adenocarcinoma of prostate). Of the latter group, 11 cases of prostate cancer in the PSA range of 4-20 ng/ml were included for studying the diagnostic utility of combination of both serum PSA and glyoxalase. Results: In prostate cancer cases with PSA in the range of 4-20 ng/ml, the glyoxalase was found to be 233.3 ± 98.6 μmol/min while for the non-malignant group it was 103.1 ± 19.7 μmol/min. A cut-off of 19.2 ng/ml PSA showed sensitivity of 9...

Combination of Channel-TURP and ILC versus Standard TURP or ILC for Elderly with Benign Prostatic Hyperplasia: A Randomized Prospective Trial

Urologia Internationalis : Last 20 articles — Thu, 29 Sep 2011 23:00:00 +0100

Urol Int (DOI:10.1159/000331500) (Source: Urologia Internationalis : Last 20 articles)

MR Imaging–guided Cryoablation for the Treatment of Benign Prostatic Hyperplasia

Journal of Vascular and Interventional Radiology : JVIR — Thu, 29 Sep 2011 22:36:47 +0100

Abstract: A patient with benign prostatic hyperplasia presented with chronic lower urinary tract symptoms despite prior surgery and continued medical therapy. Using a magnetic resonance imaging–guided transperineal approach, two cryoprobes were placed into the transition zone of the prostate gland, and two cryoablation freeze-thaw cycles were performed. At 10 weeks after treatment, the frequency of nocturia had decreased from once every 1.5 hours to once per night, urinary peak flow rates had increased from 5.1 mL/s to 10.3 mL/s, and postvoid residual urinary bladder volume had decreased from 187 mL to 58 mL. Improved flow rates and symptoms remained stable 16 weeks after treatment. (Source: Journal of Vascular and Interventional Radiology : JVIR)